



## **Zogenix Secures \$35 Million Debt Facility And Raises \$15 Million Investment Capital**

SAN DIEGO, Calif., July 13, 2010 — Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, announced that it has secured a \$35 million debt facility led by Oxford Finance Corporation which also included Silicon Valley Bank. The facility consists of a \$25 million term loan and a \$10 million revolving line of credit. Concurrently, all existing Zogenix investors, including Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Abingworth Management, and Chicago Growth Partners, have provided an additional \$15 million investment.

The financing will be used to satisfy working capital needs in the commercial launch of SUMAVEL™ DosePro™ (sumatriptan injection) needle-free delivery system, the company’s first FDA-approved product, and the ongoing Phase 3 clinical development program of ZX002, a novel oral controlled-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain. Proceeds will also be used to fully repay the outstanding balance of an existing term loan.

“This funding enhances our financial strength as we continue to focus on the successful launch of our first product, SUMAVEL DosePro,” said Ann Rhoads, chief financial officer at Zogenix. “The additional support from our investors represents their commitment to the growth of our company and the development of our pipeline.”

“Oxford is pleased to participate in the financing package Zogenix has secured to further the growth of its company,” said Chris Herr, managing director of Oxford Finance Corporation. “Zogenix has a strong management team that is leading their FDA-approved product to commercial success.”

“The financing we are providing Zogenix will offer the flexibility the company needs to continue to meet its strategic objectives,” said Michael White, senior relationship manager, Life Sciences, from Silicon Valley Bank in San Diego. “We are pleased to help Zogenix and many other life science companies in the San Diego market meet their goals.”

## **About Zogenix**

Zogenix, Inc., with offices in Emeryville and San Diego, Calif., is a privately held pharmaceutical company focused on the development and commercialization of medicines to treat neuroscience disorders and pain. The company is commercially focused on SUMAVEL™ DosePro™ (sumatriptan injection) needle-free delivery system, which launched in January 2010, for the acute treatment of migraine and cluster headache. The company's pipeline includes ZX002, a novel oral controlled-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain, which entered Phase 3 clinical trials in March 2010. Zogenix also plans to license the patented DosePro needle-free drug delivery system to other companies. For additional information, please visit [www.zogenix.com](http://www.zogenix.com).

## **About Oxford Finance Corporation**

A subsidiary of Sumitomo Corporation, Oxford is a specialty finance firm providing senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over \$1.5 billion in loans, with lines of credit ranging from \$500 thousand to \$40 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California and Massachusetts. For more information visit [www.oxfordfinance.com](http://www.oxfordfinance.com).

## **About Silicon Valley Bank**

Silicon Valley Bank (SVB) is the premier commercial bank for companies in the technology, life science, venture capital, private equity and premium wine industries. SVB provides a comprehensive suite of financing solutions, treasury management, corporate investment and international banking services to its clients worldwide. Through its focus on specialized markets and extensive knowledge of the people and business issues driving them, Silicon Valley Bank provides a level of service and partnership that measurably impacts its clients' success. Founded in 1983 and headquartered in Santa Clara, Calif., the company serves clients around the world through 26 US offices and international operations in China, India, Israel and the United Kingdom. Silicon Valley Bank is a member of global financial services firm SVB Financial Group (Nasdaq: SIVB) and a member of the FDIC and the Federal Reserve System. More information on the company can be found at [www.svb.com](http://www.svb.com).

SUMAVEL and DosePro are trademarks of Zogenix, Inc.

# # #

### **INVESTORS:**

Ann Rhoads | Zogenix, Inc.  
858.436.8583 | [ir@zogenix.com](mailto:ir@zogenix.com)

### **MEDIA:**

Catherine O'Connor | Zogenix, Inc.  
858.436.3374 | [coconnor@zogenix.com](mailto:coconnor@zogenix.com)

Shelly Davis | Oxford Finance Corporation  
888.471.0174 | [sdavis@oxfordfinance.com](mailto:sdavis@oxfordfinance.com)